Skip to main content
Premium Trial:

Request an Annual Quote

Cadus Sells $5 Million Of Stock to SmithKline

Premium

TARRYTOWN, NY--Cadus Pharmaceuticals, a biotech company here engaged in discovery of small-molecule therapeutics, announced that it exercised an option acquired through its functional genomics collaboration with SmithKline Beecham in 1997 to sell $5 million of its common stock to the bigger pharmaceutical company. SmithKline purchased 660,962 shares of Cadus common stock at a approximately $7.56 per share. Cadus now has $42.5 million in cash and cash equivalents. Cadus develops proprietary technologies that exploit the similarities between yeast and human genomes to create drug discovery tools and to elucidate gene function and cell signaling pathways.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.